Non-small cell lung cancer metastatic Trials in Grenoble, France
Conditions / Non-small cell lung cancer metastatic / Grenoble, France
Non-small cell lung cancer metastatic has been the subject of sustained clinical investigation across multiple research sites.
11 total trials for this combination
Showing top 10 of 11 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04619004 | HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04111705 | Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer | COMPLETED | PHASE2 |
| NCT03977194 | Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04154956 | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03469960 | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr | COMPLETED | PHASE3 |
| NCT07420439 | Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease | NOT_YET_RECRUITING | — |
| NCT04233021 | Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation | COMPLETED | PHASE2 |
| NCT01798485 | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC | TERMINATED | PHASE3 |
| NCT02117167 | SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | COMPLETED | PHASE2 |
| NCT03845270 | Her2-positive Lung Cancer Treated With Dedicated Drug | COMPLETED | PHASE2 |